The Myb protein was first identified as an oncogene that causes leukemia in chickens. Since then, it has been widely associated with different types of cancers and studied in detail in myeloid leukemias. However, despite these studies, its role in the induction, pathogenesis and maintenance of AML, and other blood disorders, is still not well understood. Recent efforts to uncover its plethora of transcriptional targets have provided key insights into understanding its mechanism of action. This review evaluates our current knowledge of the role of Myb in leukemia, with a particular focus on AML, from the vast literature spanning three decades, highlighting key studies that have influenced our understanding. We discuss recent insights into its role in leukemogenesis and how these could be exploited for the therapeutic targeting of Myb, its associated co-regulators or its target genes, in order to improve outcomes in the treatment of a wide range of hematopoietic malignancies.
INTRODUCTION
The Myb family The Myb protein is part of a family of transcription factors first identified as the v-Myb transforming proteins expressed by two different avian leukemia viruses, the avian myeloblastosis virus and the E26 virus. These viruses transform immature hematopoietic cells in vitro and induce acute leukemias in chickens. 1, 2 Following the discovery and molecular cloning of the v-myb oncogene, it has been possible to study its normal cellular counterpart, c-myb/MYB. The myb gene family consists of other members, mybl1 (encoding Mybl1 or A-Myb) and mybl2 (encoding Mybl2 or B-Myb), which have different roles in various tissues. A more detailed review of these other family members can be found elsewhere. 3 This review will focus on c-myb/MYB.
The Myb protein The 75 kDa c-Myb protein is a DNA-binding transcription factor that recognizes the consensus sequence PyAACG/TG. 4, 5 The Myb protein has three distinct functional domains (Figure 1 ), an N-terminal DNA-binding domain (DBD), a centrally located transactivation domain (TAD) and a C-terminal negative regulatory domain (NRD). As a transcriptional regulator, Myb interacts with various co-regulators to carry out its functions. The DBD of Myb is known to interact with several co-repressors including N-CoR and c-Ski, 6 as well as co-activators such as Mi2a and FLASH, 7, 8 that have been shown to influence Myb's transcriptional activity. The TAD, similar to some other transactivation domains, contains clusters of acidic residues and has been shown to interact with the co-activator CBP/p300, 9,10 the TIP60 co-repressor 11 and Menin, 12 all of which have an effect on its leukemogenic activity (discussed further below). The negative regulatory function of the carboxyterminal region of Myb was first demonstrated through studies, which showed that its deletion led to increases in the DNA binding, 13 transactivation 14 and transforming abilities 15, 16 of the Myb protein. The NRD is believed to act at least in part by the recruitment of co-repressors, such as TIF1b and Mybbp1a, that interfere with target gene activation. 6, 17 Moreover, this region is important for several post-translational modifications of the Myb protein including phosphorylation, sumoylation and ubiquitination, which have been shown to negatively regulate Myb's activity and stability. [18] [19] [20] The NRD also contains an EVES domain, which regulates its transcriptional activity through binding of the p100 co-activator, or alternatively, the DBD of Myb itself. 21 
Myb expression
The highest levels of c-myb mRNA expression are found predominantly in immature hematopoietic cells as demonstrated by examination of its expression among different tissues and cells of all hematopoietic lineages. 22 It has also been shown that levels of c-myb mRNA decrease as the cells progress towards terminal differentiation 22, 23 consistent with a role in cellular proliferation and/or differentiation. Expression of c-myb is not solely restricted to the hematopoietic lineages, as it has been detected in colonic epithelial cells and at high levels in malignant colonic and breast epithelia 24, 25 as well as in several other normal and cancer cell types. 26 
Myb in normal hematopoiesis
The c-myb proto-oncogene and its product are key regulators of hematopoietic cell proliferation and differentiation. Initial experiments exposing normal human bone marrow mononuclear cells to MYB antisense oligodeoxynucleotides showed that inhibition of Myb expression resulted in a decrease in both colony size and number. 27 Its importance in hematopoietic development in vivo was first shown in c-myb null mice, which die by embryonic day 15, at which time they display a failure of (definitive) fetal liver hematopoiesis resulting in severe anemia. Similarly, all other hematopoietic lineages, except the megakaryocyte lineage, were significantly suppressed. 28 More recently, the derivation of mice bearing conditionallydeleted (floxed) alleles of c-myb has enabled a finer analysis of its role in hematopoietic differentiation. Such studies showed that c-myb is required at different stages during thymocyte development 29, 30 as well as myelopoiesis, 31 erythropoiesis, 32 B-cell development 33 and maintenance of the HSC pool. 34 Other studies have addressed this issue by introducing a c-myb transgene expressed under the control of a tetracyclineregulated promoter into a c-myb -/-embryonic stem cell line. This enabled controlled induction of Myb expression at various stages of hematopoietic development, and showed again that appropriate levels of Myb expression are required at distinct differentiation steps of each haemopoietic cell lineage. 35 Myb levels have also been manipulated in vivo through the use of a fortuitous 'knock-down' allele of murine c-myb. 36 These studies revealed differential effects of Myb reduction on the various hematopoietic sub-lineages and importantly, showed that even very substantial reductions in Myb expression were compatible with adult viability (albeit at a reduced level) and thus are not equivalent to total loss of c-myb.
Other studies using the potent germline mutagen N-ethyl-Nnitrosourea (ENU) in mice have generated mice bearing point mutations in c-myb. One such screen identified strains with point mutations in the DBD and NRD domains that exhibited a myeloproliferative syndrome and supraphysiological expansion of megakaryocyte and platelet production in the absence of thrombopoietin signaling. 37 Two further ENU mutagenesis studies reported mouse strains harboring point mutations in the TAD of the protein. 38, 39 The biological consequences of these mutations included thrombocytosis, megakaryocytosis, anaemia, lymphopenia and the absence of eosinophils, as well as a substantial increase in the number of HSCs. Both of these Myb TAD mutants were defective in their ability to interact with p300. Interestingly, other mouse studies describing point mutations in the KIX domain of p300, which directly interacts with Myb, also show hematopoietic abnormalities in multiple lineages, 40, 41 including some that closely resemble the abnormalities seen in the c-myb ENU mutants. Thus, the above-mentioned studies have generated hypomorphic alleles of c-myb that led to significant abnormalities in cells of several hematopoietic lineages.
In summary, it is clear that c-myb is required for the generation and normal function of all hematopoietic lineages. In contrast to total absence, reduced Myb levels can be tolerated, as can forms of Myb with point mutations that affect its activity. This bodes well for the notion of therapeutically inhibiting Myb activity as it suggests that substantial functional inhibition could be tolerated by patients; this will be discussed further below.
MYB AND LEUKEMIA
MYB as a driver of leukemogenesis Studies in animal systems. As mentioned above, myb was first identified as an oncogene in retroviruses that induced leukemias. Avian myeloblastosis virus was shown to cause myeloblastic leukemia in chickens and transforms only cells of the myelomonocytic lineage in vitro, whereas E26 induces a mixed erythroblastic and myeloblastic leukemia in chickens and quails and transforms immature cells of both the erythroid and myelomonocytic lineages in vitro. 42, 43 Studies in animal and cell line model systems provided further evidence for Myb's leukemogenic potential. Several studies showed that ectopic expression of Myb contributed to the transformed state by imposing a block of differentiation in leukemic cell lines representing several lineages. 44, 45 Suppression of differentiation and continued proliferation of myeloid cells by myb could also be recapitulated by ectopic expression in primary murine cells. 15 Moreover, the c-myb locus has been a site of recurrent retroviral insertional mutagenesis in several murine hematopoietic malignancies. [46] [47] [48] [49] Taken together, these observations underscore the potential of MYB activation to contribute to leukemia in humans.
Myb's differentiation-blocking activity was shown to be exerted by its DBD and TAD, which together were sufficient to induce a block of differentiation, with its C-terminal domain (which is truncated in v-Myb) acting as a negative regulator. 13, 15, 50, 51 Hence, through mechanisms including those described above, the NRD renders the c-Myb protein weaker than its retroviral and truncated counterparts in transforming hematopoietic cells, 13, 15, 51 possibly explaining its insufficiency as a sole driver of leukemogenesis. However, upon co-expression with other constitutive signaling molecules, it has been shown to cooperate and contribute to myeloid transformation. 52, 53 Indeed in the avian system at least, leukemogenesis requires activation of autocrine growth factor production. 54 Direct involvement in human leukemia. Given the compelling evidence for a widespread causative role in leukemias of both birds and mammals, its role in human leukemogenesis has, unsurprisingly, been of substantial interest. Here we will briefly discuss to some of the key findings which are summarized in Table 1 .
MYB mRNA is expressed at high levels in most human myeloid and acute lymphoid leukemias. 22 Although there are earlier reports of abnormalities in the MYB locus (6q22-24) in myeloid and lymphoid leukemias as well as lymphomas, [55] [56] [57] such alterations appeared to be rare and thus were only suggestive of an important role of MYB in human leukemogenesis. This rarity may have been due, in part, to a lack of appropriately sensitive technologies to recurrently detect these or more subtle alterations (see below). The advent of more sophisticated technologies such as high-resolution genome-wide array CGH enabled more detailed and sensitive analyses of genomic alterations in human leukemias. Two groups in 2007 reported the occurrence of recurrent chromosomal translocations and duplications in the MYB locus of patients with T-cell acute lymphocytic leukemias. 58, 59 These translocations juxtapose the T-cell receptor and MYB loci, defining a new class of T-cell acute lymphocytic leukemias that expresses higher levels of MYB, presumably due to an enhancer present in the T-cell receptor locus. The recurrent duplications appeared to be mediated by Alu elements that flank the MYB locus. These duplications were also shown to occur at low frequency during normal thymocyte development and to be clonally selected during the molecular pathogenesis of human T-cell acute lymphocytic leukemias. 60 Subsequently, recurrent copy number alterations were also reported in the MYB locus in specific subsets of AML patients that harbor a chromosomal translocation t(8;16)(p11;p13) involving MYST3 and CREBBP. 61 More recent studies have reported the occurrence of MYB-GATA1 translocations in infant acute basophilic leukemias and in one case of acute monocytic leukemia. 62, 63 These genomic analyses reveal that recurrent abnormalities in MYB do occur in leukemia, but at fairly low frequencies, particularly in myeloid leukemia. While these observations and studies in animal systems clearly show MYB's leukemogenic potential, they leave open the question of the role that MYB has in the development of majority of leukemias where it (apparently) remains unaltered.
The emerging role of Myb as an essential cofactor in the induction and maintenance of myeloid leukemia Much of what follows here will focus on myeloid leukemia, as historically a surprisingly large proportion of studies on the role of MYB in leukemia have dealt with this subtype, despite evidence, summarized above that MYB is also causatively involved in lymphoid leukemia. Perhaps this is a reflection of the fact that the avian viruses carrying v-myb oncogenes transform myeloid cells, and the discovery of frequent retroviral insertions in mouse myeloid leukemias. Myeloid transformation is also probably easier to study in vitro.
Before discussing the 'cofactor' role of MYB in AML in detail, it is worth briefly summarizing the key features and known genetic drivers of this disease. Many excellent publications including those of Dash and Gilliland 64 and Kelly and Gilliland 65 provide comprehensive reviews of this disease. Leukemia is characterized by clonal expansion of aberrant stem/progenitor cells that show increased proliferation, self-renewal and a block of differentiation, due to the accumulation of mutations in oncogenes and tumor suppressors. 64, 65 The two events required for the onset of leukemogenesis can be broadly generalized as: firstly, acquisition of an abnormality in differentiation commitment leading to a higher number of progenitor cells, that is, a block of differentiation and secondly, acquisition of the ability to proliferate independently of or with reduced requirement for extrinsic growth factors. 66 Chromosomal translocations are the leading known drivers of aberrant differentiation in the pathogenesis of AML. Several hundred of these have been reported; however, a limited number of recurring translocations-PML-RARa, AML1-ETO, CBFb-SMMHC and MLL-fusions-make up the majority. 65 Some of these translocations affect transcription factors that are critical for normal myeloid differentiation such as the core-binding factors (particularly Runx1/AML1 and CBFb) and RARa. On the other hand, MLL-fusions such as MLL-ENL and MLL-AF9 act through epigenetic mechanisms, utilizing cofactors such as the histone methyltransferase DOT1L, to induce constitutive activation of its targets HOXA9 and MEIS1. 67 In any case, early studies from the Gewirtz 68 laboratory using antisense oligodeoxynucleotides showed the sensitivity of leukemia cell lines as well as primary human AML and CML blasts to MYB inhibition, implying that it was necessary for maintenance, even if it were not sufficient for induction, of leukemia. Significantly, these studies also suggested that myeloid leukemias may be more sensitive to MYB inhibition than normal hematopoietic cells. 68, 69 Confirmation of these observations, and insight into the molecular mechanisms behind them, have come only quite recently with the development of more powerful experimental systems and technologies.
Studies using an inducible MLL-ENL oncogene reported Myb to be an essential downstream target of MLL fusion-and HoxA9/ Meis1-induced leukemic transformation, 70 a finding confirmed and expanded upon by other studies. [71] [72] [73] Correspondingly, transformation by MLL-ENL through HoxA9/Meis1 was inhibited by relatively modest (65%) short-hairpin RNA-mediated knockdown of c-myb. This was one of the few studies to link Myb, an otherwise 'orphaned'transcription factor, to a pathway utilized during leukemic transformation. That Myb was shown to be downstream of causative genetic events (MLL-ENL in this case) and not the driving factor itself represented an important step in the understanding of its role in leukemogenesis. Further studies on MLL fusion-induced leukemogenesis showed that Myb was required for the maintenance of the leukemic stem cell transcriptional signature, and that Myb knock-down led to a decrease in leukemic stem cell frequencies. 72 Importantly, the ability of MLL-ENL to induce leukemias in mice was severely impaired when the levels of Myb were knocked down even to half of the normal levels.
Other recent studies on c-myb in a mouse AML model found that Myb was downregulated upon short-hairpin RNA-mediated knockdown of MLL-AF9, and that the Myb promoter was occupied by the fusion protein. 73 Importantly, Myb was shown to be required for the maintenance of MLL-AF9 leukemias, and to regulate a self-renewal program that is essential for leukemogenesis but more dispensable for normal hematopoiesis. Furthermore, Myb knockdown led to complete remission in the MLL-AF9 mice, which was durable in most cases, in contrast to conventional chemotherapy (Ara-C þ Doxorubicin). An additional role of MYB in MLL fusion-induced leukemias was revealed when the Myb protein was found to interact through its TAD with Menin to form a complex with MLL itself and with MLL fusions. 12 This interaction of MLL with Myb was shown to be essential for the histone methyltransferase activity of MLL, which promotes global H3K4 methylation and is likely to be important for MLL-mediated transformation. Finally, it appears from structural studies with recombinant proteins that both Myb and MLL can interact simultaneously with the coactivator CBP (and presumably also p300) through the KIX domain of the latter. [74] [75] [76] As we discuss below, p300 is an important coactivator of Myb and is essential for Myb's role in leukemic transformation. These findings raise the intriguing possibility that the three proteins could be involved in a complex that enables Myb target gene regulation and MLL-mediated histone modification, which, in combination, promote leukemic transformation. Confirmation will await the demonstration that such a complex does in fact form in vivo with the relevant cellular proteins. Interestingly though, Leu628 of the KIX domain of CBP was identified as an essential residue for interaction with the TAD of MLL using NMR spectroscopy. 74 The nearby Leu630 residue of the p300 KIX domain has been shown to be involved in interaction with Myb in an ENU-generated mouse pedigree, Plt6, 41 consistent with the notion of an intimate connection in vivo.
Taken together, these studies on experimental MLL fusioninduced AML were important in establishing the essential roles of MYB in transformation and the maintenance of the leukemic stem cell in this form of AML. They further implied that targeting MYB could be efficacious in at least some forms of the disease.
The requirement for MYB is not confined to MLL fusion-induced leukaemogenesis. Significantly, the study of Hess et al. 70 also showed that more extensive suppression of Myb (to o10% of wild-type levels) prevented myeloid transformation by another oncogene, E2A-HLF. Other studies have now shown that MYB is required for BCR-ABL-induced myeloid transformation 77 and B-cell ALL. 78 Moreover, our own studies using mice carrying a hypomorphic allele of Myb (Booreana 38 ) have shown that Myb activity is required for transformation and leukaemogenesis by another human myeloid oncogene, AML1-ETO (DRP and TJG, unpublished observations; see also below), which accounts for over 10% of all cases of adult AML. 79 From these studies, the pioneering studies of Gewirtz and colleagues, as well as many other studies with myeloid leukemia cell lines, it is becoming increasingly clear that MYB is essential for the initiation and/or maintenance of many/most myeloid leukemias.
Myb target genes in leukemogenesis
To understand the role of Myb in leukemia it is essential to identify and characterize the genes that it regulates. A substantial number of Myb target genes have been identified to date, 26 including genes that have diverse functions in processes such as myeloid differentiation, cellular proliferation, cell cycle, apoptosis and cell signalling. Genes that have a major role in oncogenesis such as myc and bcl-2 have been shown to be direct Myb targets. 26 However, until recently, the established set of Myb-regulated genes could not account for its ability to impart a block of differentiation in hematopoietic cells and contribute to the process of leukemogenesis. A recent in-depth ChIP-Seq analysis of genome-wide Myb-binding regions, in conjunction with expression profiling, identified a large number of novel Myb regulated genes. 80 Traditionally, Myb has been recognized as a transcriptional activator, however, the identification of several corepressor molecules that interact through different Myb domains (see Figure 1) implied that it could act also as a repressor. 6 Indeed, Zhao et al. 80 found that almost half of the Myb-regulated genes identified in their study were in fact repressed by Myb. Importantly, several genes that have key roles in myeloid differentiation such as runx1, sfpi1 and cebpb, amongst others, were repressed by Myb. Moreover, interaction with CBP/p300 was also shown to be required for the ability of Myb to repress some key targets. Given that this interaction is essential for Myb's transforming activity, 81 these findings implied a novel role in gene repression (by mechanisms that are not yet clear) for this ubiquitous co-activator in leukemic transformation.
The study of Zuber et al. 73 mentioned above also examined genes that were differentially expressed upon Myb knockdown in MLL-AF9-induced leukemic cells. These authors found that 440% of Myb-regulated genes that were involved in the maintenance of the leukemic program were also MLL-AF9 target genes, including some well-established Myb target genes such as myc and bcl-2 that could contribute to leukemic transformation. This is entirely consistent with the authors' own work, 80 which showed an extensive overlap between Myb target genes and the signature of MLL-fusion induced leukemia-initiating cells defined by Somervaille et al. 72 Hence, the transcriptional program controlled by Myb has an important role in the initiation and maintenance of leukemias that are induced by oncogenic MLL fusion proteins. It appears that other oncogenes are also able to utilize and possibly manipulate a Myb-regulated transcriptional program as part of their leukemogenic activities. Indeed our study on the role of Myb in AML1-ETOinduced transformation and leukaemogenesis (DRP and TJG, unpublished observations) identified a set of Myb target genes that were differentially expressed between AML1-ETO-expressing cells in the presence of WT or hypomorphic alleles of c-myb. Moreover, some of these genes appeared to be regulated by both AML1-ETO and Myb. Thus even though MYB is not altered in most AML cases, activation and repression of key Myb target genes might be critical events required for transformation. In Figure 2 , we illustrate possible relationships between Myb, oncogenic fusion proteins and their target genes in myeloid leukemogenesis. In one scenario, there may be no interaction between Myb and the leukemia oncogene, even though genes regulated by each are essential for AML induction or maintenance (Figure 2a) . Alternatively, the leukemia oncogene might affect the activity of Myb ( Figure 2b) ; one example would be the case of MLL-fusions discussed above where these oncogenes appear to promote MYB expression through Meis1 and HoxA9. Finally, some target genes that are critical for leukemogenesis might be co-regulated by Myb and the AML oncogene (Figure 2c ). All of these scenarios, each of which may be relevant for different oncogenes, can explain why Myb appears to be indispensable for leukemogenesis as suggested by studies over 20 years ago. 68 Although the entire repertoire of Myb-regulated genes that are required for this process has not been completely unveiled, our current knowledge provides enough evidence to make MYB an attractive target for therapeutic intervention in myeloid leukemia.
TARGETING MYB IN HUMAN LEUKEMIAS Suppression of Myb expression by antisense and RNA interference
The use of antisense nucleic acids against Myb was pioneered by Gewirtz and colleagues who showed its efficacy in leukemia cell lines and primary patient samples. 68, 69 They were also shown to be effective in vivo in a SCID mouse model of leukemia using the K562 cell line, 82 but only showed limited success in a pilot Phase I clinical trial on CML patients. 83 However, the advent of RNA interference made this the mode of choice for specifically knocking-down gene expression. Suppression of Myb using short-hairpin RNA was successful in achieving a complete remission in mouse models of AML that are triggered by MLL-AF9, with most animals remaining relapse-free. 73 The shRNAs used enabled knockdown of Myb to almost 10% of the endogenous levels, mimicking a hypomorphic phenotype. Surprisingly, this level of endogenous Myb was shown to be sufficient for reconstitution of normal hematopoiesis in transplanted animals; however, it was clearly not enough to support leukemic transformation by MLL-AF9. This indicates that there may be a window that could be exploited therapeutically, whereby suppression of Myb would preferentially target the leukemic cells, as these appear to be more dependent on high MYB expression levels. However, while the use of RNA interference in clinical therapy is still under intense study and development, it has been hindered to date by problems with delivery and toxicity. 84 Targeting transcriptional elongation regulation of Myb Productive transcription of the MYB gene is predominantly regulated by elongation control. 85 The first intron of MYB contains two adjacent motifs that appear to be responsible for a blockade of transcription through this region. The first of these is a poly (dT) tract of 19-23 residues that is preceded by a second sequence that potentially encodes a transcript capable of forming an RNA stem loop sequence. 86, 87 It has been proposed that this leads to RNA polymerase II stalling and the generation of an RNA stem loop that can serve as a docking site for proteins involved in elongation control. In colon cancer, the poly (dT) tract is shortened and/or the sequence that encodes the stem loop is mutated, allowing an increase in transcriptional read-through. 86 In breast cancer cells, the estrogen receptor, when bound to estradiol, interacts with the gene to relieve the elongation arrest. 88 Several studies have looked into the mechanism of the elongation block in hematopoietic cells and how it is overcome in MYB-expressing cells; these have reported involvement of complexes of proteins such as NF-kB (RelB) and c-Jun. 85, 89 Targeting interactions between complexes, which act to relieve the elongation block, and the intronic region of c-myb, could be a strategy that might prove efficacious in leukemia as well as other types of cancer. Similarly, targeting those protein complexes themselves may be able to suppress MYB expression. Transcription factor-DNA complexes have been targeted previously by the use of small molecules inhibitors in the case of Hif-1, 90 while a modified peptide has been used to suppress protein-protein interactions in the case of Notch. 91 Another attractive strategy would be to use small molecules to inhibit the activity of components of the transcriptional elongation machinery. In particular, Flavopiridol inhibits the activity of the Cdk9 subunit of P-TEFb (positive transcription elongation factor b), which we have recently shown to be critical for estrogen receptor-mediated promotion of MYB transcriptional elongation, 92 and may be similarly required for MYB expression in leukemia. Alternatively, it is interesting to speculate that the bromodomain protein Brd4, which is known to recruit P-TEFb, 93 may also be involved in controlling MYB transcriptional elongation. Zuber et al. 73 have reported an extensive overlap between genes regulated by Myb and those affected by treatment with the small molecule bromodomain inhibitor JQ1, 94 suggesting that the latter may also be effective in suppressing MYB transcription.
Targeting Myb's interaction with p300 and other partner proteins CBP/p300 was the first co-activator identified to interact with Myb, and influence its transcriptional activity. 9, 10 Initial studies showed that mice harboring 'knocked-in' mutations in the KIX domain of p300, but not that of CBP, exhibited several hematopoietic abnormalities. 40 These studies implicated the Myb-p300 interaction as being critical for hematopoietic development. Further studies using ENU mutagenesis have supported this observation, 39, 41 with the latter showing that interaction of p300 is required for the hematopoietic stem cell maintenance function of Myb. We have also shown that this interaction is essential for the ability of Myb to impose a block of differentiation in primary hematopoietic cells. 81 A more recent study isolated another ENU pedigree, Booreana, which also harbors a point mutation in Myb (E308G) that disrupts its interaction with p300, 38 and which exhibited similar hematopoietic abnormalities to those reported previously. 39 However, despite no detectable interaction between Myb and KIX, such mice are able to survive for up to one year, indicating that hematopoietic development could occur despite major disruption to the interaction between these two proteins. Hematopoietic cells from these mice are unable to be transformed in vitro by MLL-fusions or AML1-ETO (DRP and TJG, unpublished). We have also observed that these mice, unlike wild-type mice, are resistant to developing AML when transplanted with hematopoietic stem/progenitor cells expressing AML1-ETO. These observations imply that critical components of the Myb-dependent transcriptional program that are essential for leukemic transformation (as discussed above) specifically require the interaction of Myb with p300. Hence, targeting this specific protein-protein interaction could have therapeutic benefit in multiple subtypes of AML.
The interacting region between the Myb TAD and the KIX domain of CBP/p300 has been studied in depth by NMR, providing detailed information about essential residues and binding surfaces. 95 Based on this, the development of small molecule inhibitors or peptides could be designed, first for proof-ofprinciple studies, and eventually for development for use in the clinic. However, protein-protein interactions have generally been regarded as not constituting desirable drug targets, unlike tyrosine kinases whose enzymatic activity is readily amenable to inhibition by small molecules. Nevertheless, overcoming a complex disease like cancer by relying on targeting a single class of molecules is unlikely to be successful in many cases. For example, inhibitors of FLT3, which is activated in B25% of all AMLs, have met with limited clinical success as single agents. 96 Moreover, the notion of targeting protein-protein interactions is now being considered seriously based on recent technical advances and discoveries. 97 Several inhibitors of protein-protein interactions like ABT-263, a small molecule that mimics interaction between the pro-survival proteins Bcl-2/Bcl-X L and BH3-only family of proteins 98, 99 and Nutlin family of small molecule inhibitors of the p53-MDM2 interaction, 100 are currently in clinical trials for various cancers. 101, 102 Other strategies for targeting protein-protein interactions are also being developed; for example, 'stapled' peptides have been successfully used for blocking the interactions between Bcl-2 family members 103 and for components of the Notch transcription factor complex 91 in leukemia cells. These examples show that our view of what can be therapeutically targeted is changing and that targeting of the interaction of Myb with p300 may well be feasible. It should also be noted that Myb interacts with many other proteins [6] [7] [8] 17, 104 and that targeting these interactions may also be therapeutically useful. For example Myb is known to interact with Menin, which in turn recruits MLL. 12 This interaction appears to be important for leukemic transformation by MLL-ENL, 12 and thus it is worth noting that recently small molecules that block the Menin-MLL interaction have been reported. 105 If development of molecules that disrupt interactions between Myb and its partner proteins proves successful, such molecules should be tested both singly and in combination with conventional chemotherapeutics or molecularly targeted drugs.
Targeting downstream effectors of MYB Another approach for exploiting the dependency of leukemia on MYB would be to identify and target essential downstream effectors of Myb, which may include some of those discussed above. However the main advantage of such an approach would lie in the identification of critical Myb targets for which inhibitors already exist or which are more readily 'druggable' than Myb itself. In fact our studies and those of others have already made progress in this direction. 73, 80 For example, as mentioned above, there are already small molecule inhibitors of the well-documented Myb target, Bcl-2. Several studies have reported Myc to be a target of Myb in myeloid cell lines, the activity of the former being essential for that of the latter. 106, 107 Targeting Myc-another transcription factor-could pose similar or greater challenges than targeting Myb; however, recent studies have shown promise in targeting the chromatin regulator Brd4, which is required to sustain the ability of Myc to impose aberrant self-renewal. 108 As more Myb targets that are essential for its role in leukemogenesis are identified, additional avenues for its therapeutic targeting in specific sub-types of AML will emerge.
Other approaches to targeting MYB High-throughput screens using libraries of small-molecules have routinely been used for the discovery of novel inhibitors, especially those targeting enzymes such as kinases. Such screens could be undertaken to screen for small molecules that could inhibit the sequence-specific binding of Myb to the promoters of target genes. A similar approach has previously been successful for the identification of Echinomycin, an inhibitor of HIF-1 DNAbinding activity. 90 As mentioned above, the increased sensitivity of leukemic cells to reduced levels of Myb activity could be exploited to define a targetable therapeutic window. The success of such screening strategies could greatly depend upon the assays used as a readout. A recent study generated a fluorescence-based screening system using a cell line containing a reporter with the coding region of eGFP placed downstream of the Myb-responsive mim-1 promoter. 109 Using this strategy, the authors were able to identify mexicanin-I, a sesquiterpene lactone, as an effective suppressor of Myb target genes, which consequently resulted in inhibition of proliferation of leukemic cells.
Other strategies could include inhibition of upstream regulators of Myb, even though relatively few of these have been conclusively identified to date. For example, previous work has shown that Myb activity can be enhanced by Pim-1 mediated phosphorylation. 110 Although more follow-up studies are required to understand the role of Pim-1 in Myb's transforming ability, inhibition of the former's kinase activity might present an effective way to combat the Myb-induced transcriptional program that has an essential role in leukemogenesis. Moreover, Pim-1 kinase inhibitors have recently been shown to be effective in various cell lines and primary leukemias. 111 In similar vein, strategies that target regulators of Myb protein stability could be developed. Like many proteins Myb is degraded by the ubiquitin/proteasome system; one of the proteins that target Myb for ubiquitylation is Fbw7, 112 the binding of which appears to be regulated by Myb phosphorylation. This in turn raises the prospect of modulating the kinase pathways that regulate Myb phosphorylation as a therapeutic strategy. Indeed, it has been reported that, somewhat counter-intuitively, small-molecule inhibition of GSK3b promotes Myb degradation, 113 although some apparently contradictory findings have also been reported. 114 
CONCLUSIONS
While the important roles of MYB in hematopoiesis and its multiple links to leukaemogenesis have been known for some time, it has only recently started to become clear that many leukemias seem to be particularly dependent on this gene. This immediately highlights its value as a potential target, and several studies now suggest there may be a significant therapeutic window for agents that block MYB and/or its leukemia-promoting functions. Moreover, while transcription factors have traditionally been considered difficult or impossible to target in a therapeutic context, this conceptual barrier is gradually being eroded. New insights into MYB itself, as well as advances in technology and emerging examples of successful targeting of transcription factors with peptides or small molecules, all augur well for the development of therapeutics that suppress MYB activity. It is to be hoped that one or more of these approaches bears fruit and eventually helps to reduce the morbidity and mortality due to leukemia.
